RAAS blockers in hypertension posing a higher risk toward the COVID-19

Dermatol Ther. 2020 Jul;33(4):e13501. doi: 10.1111/dth.13501. Epub 2020 Jun 16.

Yogendra Singh¹, Gaurav Gupta², Saurabh Satija^{3

4}, Poonam Negi⁵, Dinesh K Chellappan⁶, Kamal Dua^{3

7

8}

¹ Mahatma Gandhi College of Pharmaceutical Sciences, Jaipur, India.
² School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India.
³ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney (UTS), Sydney, New South Wales, Australia.
⁴ School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
⁵ School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, India.
⁶ Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
⁷ Centre for Inflammation, Centenary Institute, Sydney, New South Wales, Australia.
⁸ Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) and School of Biomedical Sciences and Pharmacy, The University of Newcastle (UoN), Callaghan, New South Wales, Australia.

No abstract available

Publication types